6/18/2021  5:36:14 PM Chg. -0.30 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
85.18EUR -0.35% 814,100
Turnover: 69.27 mill.
84.00Bid Size: 132 85.50Ask Size: 97 15.93 bill.EUR 1.46% 20.14

Business description

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
 

Management board & Supervisory board

CEO
Jean-Christophe Tellier
Management board
Sandrine Dufour, Bill Silbey, Charl van Zyl, Dhaval Patel, Emmanuel Caeymaex, Iris Löw-Friedrich, Jean Luc Fleurial, Kirsten Lund-Jurgensen
Supervisory board
Albrecht De Graeve, Charles-Antoine Janssen, Countess Evelyn du Monceau, Cyril Janssen, Jan Berger, Jean van Rijckevorsel, Jean-Christophe Tellier, Kay Davies, Pierre Gurdjian, Roch Doliveux, Susan Gasser , Ulf Wiinberg, Viviane Monges
 

Company data

Name: UCB SA
Address: Allée de la Recherche 60,B-1070 Brussels
Phone: +32-2-559-9999
Fax: +32-2-559-9900
E-mail: contactucb@ucb.com
Internet: www.ucb.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 48.82%
IPO date: -

Investor relations

Name: Antje Witte
IR phone: +32-2-559-9414
IR Fax: -
IR e-mail: investor-relations@ucb.com

Company calendar

CW 31 | 7/29/2021 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
48.82%
Financière de Tubize S.A. (Tubize)
 
35.00%
Wellington
 
8.01%
BlackRock
 
5.01%
eigene Anteile
 
3.16%